Rivaroxaban and stroke prevention in patients with atrial fibrillation: new evidence

References

• Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010;31(19):2369-429
   PubMed Web of Science ®Google Scholar
• Wilke T, Groth A, Mueller S, et al. Incidence and prevalence of atrial fibrillation: an analysis based on 8.3 million patients. Europace 2013;15(4):486-93
   PubMed Web of Science ®Google Scholar
• Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and risk factors in atrial fibrillation (ATRIA) Study. JAMA 2001;285(18):2370-5
   PubMed Web of Science ®Google Scholar
• Barrios V, Calderón A, Escobar C, de la Figuera M. Patients with atrial fibrillation in a primary care setting: val-FAAP study. Rev Esp Cardiol 2012;65(1):47-53
   PubMed Web of Science ®Google Scholar
• Martínez-Rubio A, Pujol Iglesias E, Bonastre Thio M, et al. Epidemiología de la fibrilación auricular en España. Rev Esp Cardiol 2012;12(fascículo D):3-8
   Google Scholar
• Planas F, Antunez F, Poblet T, et al. Clinical profile of idiopathic paroxsysmal atrial fibrillation. (FAP registry). Rev Esp Cardiol 2011;54(7):838-44
   Google Scholar
• Nieuwlaat R, Capucci A, Camm J, et al. Atrial fibrillation management: a prospective survey in ESC Member Countries. The Euroheart survey on atrial fibrillation. Eur Heart J 2005;26(22):2422-34
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 1998;98(10):946-52
   PubMed Web of Science ®Google Scholar
• Wattigney WA, Mensah GA, Croft JB. Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999. implications for primary prevention. Circulation 2003;108(6):711-16
   PubMed Web of Science ®Google Scholar
• Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22(8):983-8
   PubMed Web of Science ®Google Scholar
• Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69(6):546-54
   PubMed Web of Science ®Google Scholar
• Skanes AC, Healey JS, Cairns JA, et al. Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol 2012;28(2):125-36
   PubMed Web of Science ®Google Scholar
• You JJ, Singer DE, Howard PA, et al. American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e531S-75S
   PubMed Web of Science ®Google Scholar
• Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012;33(21):2719-47
   PubMed Web of Science ®Google Scholar
• Kirchho FP, Curtis AB, Skanes AC, et al. Atrial fibrillation guidelines across the Atlantic: a comparison of the current recommendations of the European Society of Cardiology/European Heart Rhythm Association/European Association of Cardiothoracic Surgeons, the American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society, and the Canadian Cardiovascular Society. Eur Heart J 2013;34(20):1471-4
   Google Scholar
• Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146(12):857-67
   PubMed Web of Science ®Google Scholar
• Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev 2007(3):CD006186
   Google Scholar
• Hylek EM, Go AS, Chang Y, et al. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349(11):1019-26
   PubMed Web of Science ®Google Scholar
• Mangiafico RA, Mangiafico M. Emerging anticoagulant therapies for atrial fibrillation: new options, new challenges. Curr Med Chem 2012;19(27):4688-98
   Google Scholar
• Gallego P, Roldán V, Lip GY. Novel oral anticoagulants in cardiovascular disease. J Cardiovasc Pharmacol Ther 2014;19(1):34-44
   Google Scholar
• Barrios V, Escobar C. Rivaroxaban: a once-daily anticoagulant for the prevention of thromboembolic complications. Expert Rev Cardiovasc Ther 2013;11(2):129-41
   PubMedGoogle Scholar
• Poldermans D, Bax JJ, Boersma E, et al. Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in noncardiacsurgery: the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in noncardiacSurgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA). Eur Heart J 2009;30(22):2769-812
   PubMed Web of Science ®Google Scholar
• Raunsø J, Selmer C, Olesen JB, et al. Increased short-term risk of thrombo-embolism or death after interruption of warfarin treatment in patients with atrial fibrillation. Eur Heart J 2012;33(15):1886-92
   PubMed Web of Science ®Google Scholar
• European Medicines Agency (EMA). Xarelto®, “Summary of product characteristics”. Updated 15-August-2013. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000944/WC500057108.pdf
   Google Scholar
• Thomas TF, Ganetsky V, Spinler SA. Rivaroxaban: an oral factor Xa inhibitor. Clin Ther 2013;35(1):4-27
   Google Scholar
• ROCKET AF Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study. Am Heart J 2010;159(3):340-7
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011;365(10):883-91
   PubMed Web of Science ®Google Scholar
• Kreutz R. Pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor XA inhibitor. Curr Clin Pharmacol 2014;9(1):75-83
   Google Scholar
• Kubitza D, Perzborn E, Berkowitz SD. The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol 2013;4:145
   PubMed Web of Science ®Google Scholar
• Mueck W, Schwers S, Stampfuss J. Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 2013;11(1):10
   PubMedGoogle Scholar
• Smythe MA, Fanikos J, Gulseth MP, et al. Rivaroxaban: practical considerations for ensuring safety and efficacy. Pharmacotherapy 2013;33(11):1223-45
   Google Scholar
• Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation 2007;116(2):180-7
   PubMed Web of Science ®Google Scholar
• Buller HR, Lensing AW, Prins MH, et al. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein-DVT Dose-Ranging Study. Blood 2008;112(6):2242-7
   PubMed Web of Science ®Google Scholar
• Kreutz R. A clinical and pharmacologic assessment of once-daily versus twice-daily dosing for rivaroxaban. J Thromb Thrombolysis 2013. [Epub ahead of print]
   Google Scholar
• Kubitza D, Roth A, Becka M, et al. Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol 2013;76(1):89-98
   PubMed Web of Science ®Google Scholar
• Kubitza D, Becka M, Roth A, Mueck W. The influence of age and gender on the pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct Factor Xa inhibitor. J Clin Pharmacol 2013;53(3):249-55
   Google Scholar
• Kubitza D, Becka M, Roth A, Mueck W. Absence of clinically relevant interactions between rivaroxaban – an oral, direct Factor Xa inhibitor--and digoxin or atorvastatin in healthy subjects. J Int Med Res 2012;40(5):1688-707
   PubMed Web of Science ®Google Scholar
• Lindhoff-Last E, Ansell J, Spiro T, Samama MM. Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med 2013;45(5-6):423-9
   PubMed Web of Science ®Google Scholar
• Molenaar PJ, Dinkelaar J, Leyte A. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation. Clin Chem Lab Med 2012;50(10):1799-807
   Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361(12):1139-51
   PubMed Web of Science ®Google Scholar
• Patel MR, Hellkamp AS, Lokhnygina Y, et al. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation). J Am Coll Cardiol 2013;61(6):651-8
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Hellkamp AS, Patel MR, et al. End of study transition from study drug to open-label vitamin K antagonist therapy: the ROCKET AF experience. Circ Cardiovasc Qual Outcomes 2013;6(4):470-8
   PubMedGoogle Scholar
• Goodman SG, Wojdyla DM, Piccini JP, et al. for the ROCKET AF Investigators. Factors associated with major bleeding events: insights from the Rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). J Am Coll Cardiol 2014;63(9):891-900
   PubMedGoogle Scholar
• Tanigawa T, Kaneko M, Hashizume K, et al. Model-based dose selection for phase III rivaroxaban study in Japanese patients with non-valvular atrial fibrillation. Drug Metab Pharmacokinet 2013;28(1):59-70
   PubMed Web of Science ®Google Scholar
• Kaneko M, Tanigawa T, Hashizume K, et al. Confirmation of model-based dose selection for a Japanese phase III study of rivaroxaban in non-valvular atrial fibrillation patients. Drug Metab Pharmacokinet 2013;28(4):321-31
   PubMed Web of Science ®Google Scholar
• Japanese Circulation Society Joint Working Group. Guidelines for pharmacotherapy of atrial fibrillation (JCS 2008): Digest version. Circ J 2010;74(11):2479-500
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. J-ROCKET AF study investigators. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study. Circ J 2012;76(9):2104-11
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. the J-ROCKET AF Study Investigators. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation in relation to the CHADS2 score: a subgroup analysis of the J-ROCKET AF Trial. J Stroke Cerebrovasc Dis 2014;23(2):379-83
   PubMed Web of Science ®Google Scholar
• Hart RG, Sherman DG, Easton JD, Cairns JA. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology 1998;51(3):674-81
   Google Scholar
• Jørgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen stroke study. Stroke 1996;27(10):1765-9
   PubMed Web of Science ®Google Scholar
• Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005;36(6):1115-19
   PubMed Web of Science ®Google Scholar
• Steger C, Pratter A, Martinek-Bregel M, et al. Stroke patients with atrial fibrillation have a worse prognosis than patients without: data from the Austrian stroke registry. Eur Heart J 2004;25(19):1734-40
   PubMed Web of Science ®Google Scholar
• Toni D, Di Angelantonio E, Di Mascio MT, the PRoFESS Study Group. Types of stroke recurrence in patients with ischemic stroke: a substudy from the PRoFESS trial. Int J Stroke 2013. [Epub ahead of print]
   Google Scholar
• Gladstone DJ, Bui E, Fang J, et al. Potentially preventable strokes in high-risk patients with atrial fibrillation who are not adequately anticoagulated. Stroke 2009;40(1):235-40
   PubMed Web of Science ®Google Scholar
• Lip GY, Laroche C, Dan GA, et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014;16(3):308-19
   PubMed Web of Science ®Google Scholar
• Lip GY, Laroche C, Dan GA, et al. ‘Real-world’ antithrombotic treatment in atrial fibrillation: the EURObservational Research Programme Atrial Fibrillation General Pilot survey. Am J Med 2014. [Epub ahead of print]
   Google Scholar
• Cowan C, Healicon R, Robson I, et al. The use of anticoagulants in the management of atrial fibrillation among general practices in England. Heart 2013;99(16):1166-72
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Patel MR, Stevens SR, et al.ROCKET AF; Steering Committee Investigators. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol 2012;11(4):315-22
   PubMed Web of Science ®Google Scholar
• Tanahashi N, Hori M, Matsumoto M, et al. J-ROCKET AF Study Investigators. Rivaroxaban versus warfarin in Japanese patients with nonvalvular atrial fibrillation for the secondary prevention of stroke: a subgroup analysis of J-ROCKET AF. J Stroke Cerebrovasc Dis 2013;22(8):1317-25
   PubMed Web of Science ®Google Scholar
• Morgan CL, McEwan P, Tukiendorf A, et al. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control. Thromb Res 2009;124(1):37-41
   PubMed Web of Science ®Google Scholar
• Wan Y, Heneghan C, Perera R, et al. Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review. Circ Cardiovasc Qual Outcomes 2008;1(2):84-91
   PubMed Web of Science ®Google Scholar
• Singer DE, Hellkamp AS, Piccini JP, et al. ROCKET AF Investigators. Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial. J Am Heart Assoc 2013;2(1):e000067
   Web of Science ®Google Scholar
• Halperin JL, Bloomgarden Z, Hellkamp A, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and diabetes: a subgroup analysis of the ROCKET AF trial. Circulation 2012;126(21 MeetingAbstracts):A15544
   Google Scholar
• Hart RG, Eikelboom JW, Ingram AJ, Herzog CA. Anticoagulants in atrial fibrillation patients with chronic kidney disease. Nat Rev Nephrol 2012;8(10):569-78
   PubMed Web of Science ®Google Scholar
• Hart RG, Eikelboom JW, Brimble KS, et al. Stroke prevention in atrial fibrillation patients with chronic kidney disease. Can J Cardiol 2013;29(7 Suppl):S71-8
   PubMed Web of Science ®Google Scholar
• Salim I, Al Suwaidi J, Ghadban W, Salam AM. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety. Expert Opin Drug Saf 2013;12(1):53-63
   PubMed Web of Science ®Google Scholar
• Piccini JP, Stevens SR, Chang Y, et al. ROCKET AF Steering Committee and Investigators. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation 2013;127(2):224-32
   PubMed Web of Science ®Google Scholar
• Fox KA, Piccini JP, Wojdyla D, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment. Eur Heart J 2011;32(19):2387-94
   PubMed Web of Science ®Google Scholar
• Hori M, Matsumoto M, Tanahashi N, et al. J-ROCKET AF study investigators. Safety and efficacy of adjusted dose of rivaroxaban in Japanese patients with non-valvular atrial fibrillation: subanalysis of J-ROCKET AF for patients with moderate renal impairment. Circ J 2013;77(3):632-8
   PubMed Web of Science ®Google Scholar
• Connolly S, Pogue J, Hart R, et al. ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial. Lancet 2006;367(9526):1903-12
   PubMed Web of Science ®Google Scholar
• Hylek EM, Frison L, Henault LE, Cupples A. Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V. Stroke 2008;39(11):3009-14
   Google Scholar
• Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115(21):2689-96
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Wojdyla D, Hankey GJ, et al. Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial. Ann Intern Med 2013;158(12):861-8
   Google Scholar
• Shaikh AY, Maan A, Heist EK, et al. Management strategies in atrial fibrillation in patients with heart failure. Cardiol Rev 2012;20(6):288-96
   Google Scholar
• Shiga T. Atrial fibrillation in patients with heart failure: treatment and management. Nihon Rinsho 2013;71(1):131-5
   Google Scholar
• Witt DM, Delate T, Clark NP, et al. Warped Consortium. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost 2010;8(4):744-9
   PubMed Web of Science ®Google Scholar
• van Diepen S, Hellkamp AS, Patel MR, et al. Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF. Circ Heart Fail 2013;6(4):740-7
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Stevens SR, White HD, et al. for the ROCKET AF Investigators. Ischaemic cardiac outcomes in patients with atrial fibrillation treated with vitamin K antagonism or factor Xa inhibition: results from the ROCKET AF trial. Eur Heart J 2014;35(4):233-41
   PubMed Web of Science ®Google Scholar
• Chatterjee S, Sharma A, Uchino K, et al. Rivaroxaban and risk of myocardial infarction: insights from a meta-analysis and trial sequential analysis of randomized clinical trials. Coron Artery Dis 2013;24(8):628-35
   PubMed Web of Science ®Google Scholar
• Chen JJ, Lin LY, Lee CH, Liau CS. Age, male gender, and atrial fibrillation predict lower extremity amputation or revascularization in patients with peripheral artery diseases: a population-based investigation. Int J Angiol 2012;21(1):35-40
   Google Scholar
• Jones WS, Hellkamp AS, Halperin J, et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014;35(4):242-9
   PubMed Web of Science ®Google Scholar
• Halperin JL, Wojdyla D, Piccini JP, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the ROCKET-AF Trial. Stroke 2012;43(2 MeetingAbstracts):A148
   Google Scholar
• Piccini JP, Stevens SR, Lokhnygina Y, et al. ROCKET AF Steering Committee & Investigators. Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol 2013;61(19):1998-2006
   PubMed Web of Science ®Google Scholar
• Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000;342(25):1887-92
   PubMed Web of Science ®Google Scholar
• Steg PG, Lopez-Sendon J, Lopez de Sa E, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007;167(1):68-73
   PubMedGoogle Scholar
• Ebertz F, Förster K, Gelbricht V, et al. Real life efficacy and safety of rivaroxaban for stroke prevention in atrial fibrillation – first results of the prospective noac registry (NCT01588119). 55th American Society of Hematology (ASH) Annual Meeting and Exposition New Orleans, LA, 7-10 December 2013 213; Abstract
   Google Scholar
• Pfeilschifter W, Luger S, Brunkhorst R, et al. The gap between trial data and clinical practice – an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. Cerebrovasc Dis 2013;36(2):115-19
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013;369(22):2093-104
   PubMed Web of Science ®Google Scholar
• Perzborn E, Gruber A, Tinel H, et al. Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates. Thromb Haemost 2013;110(1):162-72
   PubMed Web of Science ®Google Scholar
• Eerenberg ES, Kamphuisen PW, Sijpkens MK, et al. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2011;124(14):1573-9
   PubMed Web of Science ®Google Scholar
• Marlu R, Hodaj E, Paris A, et al. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost 2012;108(2):217-24
   PubMed Web of Science ®Google Scholar
• Jeske W, Escalante V, McGuire B, et al. Neutralization of hemorrhage induced by direct factor XA and thrombin inhibitors in a rat model. 55th American Society of Hematology (ASH) Annual Meeting and Exposition New Orleans, LA, 7-10 December 2013; 3644; Abstract
   Google Scholar
• Mark C, Vandana M, Michael K, et al. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), An Antidote For Fxa Inhibitors. 55th American Society of Hematology (ASH) Annual Meeting and Exposition New Orleans, LA, 7-10 December 2013; 3636; Abstract
   Google Scholar
• Kleintjens J, Li X, Simoens S, et al. Cost-effectiveness of rivaroxaban versus warfarin for stroke prevention in atrial fibrillation in the Belgian healthcare setting. Pharmacoeconomics 2013;31(10):909-18
   PubMed Web of Science ®Google Scholar
• Lee S, Anglade MW, Pham D, et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol 2012;110(6):845-51
   PubMed Web of Science ®Google Scholar
• Rognoni C, Marchetti M, Quaglini S, Liberato NL. Apixaban, dabigatran, and rivaroxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis. Clin Drug Investig 2014;34(1):9-17
   PubMed Web of Science ®Google Scholar
• Kansal AR, Zheng Y, Pokora T, Sorensen SV. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. Best Pract Res Clin Haematol 2013;26(2):225-37
   PubMedGoogle Scholar
• Harrington AR, Armstrong EP, Nolan PE Jr, Malone DC. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44(6):1676-81
   PubMed Web of Science ®Google Scholar
• Agency for Healthcare Research and Quality, prepared by Duke Evidence-based Practice Center. Comparative effectiveness review, number 123, contract no. 290-2007-10066-I. Stroke prevention in atrial fibrillation (2013). Available from: http://effectivehealthcare.ahrq.gov/ehc/products/352/1669/stroke-atrial-fibrillation-executive-130821.pdf
   Google Scholar